Insilon · Simulate
Run a drug across a whole population, not a handful of scenarios
Insilon couples PK-PD and physiology surrogates with biomolecular response models, so you can sweep dose, schedule and subgroup in hours instead of weeks.
SZ-0412 · 40 mg QD · 10,000 patients
- Median AUC
- 1,240 ng·h/mL
- 90% interval
- 610–2,380
- Predicted ORR, 12 weeks
- 31% (27–35%)
- Grade 3+ AE
- 8% (6–10%)
- Seed
- 4417
Capabilities
What Insilon does
Surrogates
Physics-ML PK-PD
Neural surrogates of physiology and PK-PD systems trained against mechanistic models with Modulus.
Molecular
Biomolecular response
Target, ligand and pathway effects from BioNeMo models feed each patient's response.
Sweeps
Dose, schedule, subgroup
Run the full grid of candidate arms across the same cohort in one job.
Uncertainty
Calibrated intervals
Every efficacy and safety output carries an interval, not a single number.
Reproducible
Deterministic runs
The same inputs, versions and seed give the same result, logged to Evidra.
Scale
Batched on GPU
Tens of thousands of coupled systems per arm, batched with TensorRT and Triton.
How it works
Inside Insilon
Load
Read the cohort and compound model.
Expose
Simulate PK across every patient.
Respond
Simulate PD, efficacy and safety.
Summarise
Return distributions with intervals.
Specification
Specification
Items marked planned are in design with pilot partners.
| Item | Detail |
|---|---|
| Models | PK-PD and physiology surrogates; BioNeMo response; outcome models |
| Scale (target) | 104 to 106 patients per run |
| Outputs | Exposure, efficacy, safety distributions with intervals |
| Reproducibility | Versioned models, seeds and inputs per run |
| Coverage | Selected therapeutic areas first; wider mechanistic coverage planned |
| Status | In development |
Place in the loop
Insilon in the Sanenza loop
- 01PopulateCohorta
Generates calibrated virtual-patient cohorts for an indication, region or rare subgroup.
- 02SimulateInsilon
Runs the compound across the whole cohort with PK-PD surrogates and biomolecular response.
- 03DesignProtova
Searches dose, cohort, endpoint and sample size, and scores every candidate protocol.
- 04Stress-testVigila
Oversamples rare subgroups to find adverse-event signals before a patient is exposed.
- 05LocalisePhysova
Renders organ-scale twins for tissue exposure and drug-device questions.
- 06ValidateEvidra
Links each prediction to the real outcome and sends recalibration back to every product.
Questions
About Insilon
How do surrogates compare with our mechanistic models?
Each surrogate is trained and checked against a reference mechanistic model, and its error against that model is reported.
Can we bring our own PK-PD model?
That is the plan: import a NONMEM or Monolix model as the reference and train a surrogate against it. This is planned with pilot partners.
How fast is a run?
The design target is under an hour for a 10,000-patient arm. Actual times depend on model depth and will be measured in pilots.
See Insilon in a briefing
We walk your team through Insilon on a public example, then discuss where a pilot could test it against outcomes you already know.